Company Profile
Nuvation Bio Stock Price, News & Catalysts
- Ticker:
- NUVB
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.93 USD (+1.46%)
Close
Last updated: August 21, 2026
1.71B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, NUVB closed up 1.46% at $6.93. No new same-company headline was identified in the current news window.
Company overview
Business overview
Nuvation Bio is an oncology company developing targeted cancer therapies and other precision-oncology assets. Its strategy is to build a focused cancer pipeline with broad therapeutic potential.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Nuvation sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical data, pipeline selection, and the ability to translate oncology programs into value.
Position Within the Biotechnology Landscape
Nuvation is a catalyst-sensitive oncology company whose valuation will depend on clinical and strategic progress.
Future catalysts
- Nuvation Bio’s catalysts are taletrectinib and any regulatory or data update in ROS1-positive lung cancer. The market will care about whether the asset can keep building a real oncology franchise.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nuvation Bio (NUVB)?
Nuvation Bio (NUVB) most recently closed at 6.93 USD, a +1.46% move versus the previous session.
What is the market cap of Nuvation Bio (NUVB)?
Nuvation Bio currently has a market capitalization of 1.71B USD on BioPharmSignal.
What does Nuvation Bio do?
Nuvation Bio is an oncology company developing targeted cancer therapies and other precision-oncology assets. Its strategy is to build a focused cancer pipeline with broad therapeutic potential.
On which exchange is NUVB stock listed?
Nuvation Bio (NUVB) is associated with NYSE, United States, Biopharma.
What is taletrectinib?
Nuvation Bio’s catalysts are taletrectinib and any regulatory or data update in ROS1-positive lung cancer.
Which conditions is Nuvation Bio targeting with taletrectinib?
Nuvation Bio is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Nuvation Bio describe recent progress with taletrectinib?
Nuvation Bio’s catalysts are taletrectinib and any regulatory or data update in ROS1-positive lung cancer.
What is Nuvation?
Nuvation Bio is an oncology company developing targeted cancer therapies and other precision-oncology assets.